HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus

Files in This Item:
63_EJ15-0438.pdf1.01 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus
Authors: Yamamoto, Chiho Browse this author
Miyoshi, Hideaki Browse this author →KAKEN DB
Fujiwara, Yutaka Browse this author
Kameda, Reina Browse this author
Ichiyama, Mei Browse this author
Nomoto, Hiroshi Browse this author
Kameda, Hiraku Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Atsumi, Tatsuya Browse this author →KAKEN DB
Keywords: Continuous glucose monitoring
Insulin degludec
Type1 diabetes mellitus
Issue Date: Jan-2016
Publisher: The Japan Endocrine Society
Journal Title: Endocrine Journal
Volume: 63
Issue: 1
Start Page: 53
End Page: 60
Publisher DOI: 10.1507/endocrj.EJ15-0438
PMID: 26522272
Abstract: To investigate the differences in glycemic variability between the long-acting insulins glargine and degludec using continuous glucose monitoring, we conducted an open-label, multicenter, prospective, observational study that enrolled 21 participants with type 1 diabetes mellitus currently receiving basal-bolus insulin therapy with glargine. To avoid the potential influence of diet and exercise on glycemic control, all participants were housed and monitored within the hospital for the duration of the study. Once glycemic control was achieved with glargine, glycemic variability was evaluated using continuous glucose monitoring for 3 days. Glargine was then replaced by degludec and glycemic variability again assessed via continuous glucose monitoring. The primary outcome measure of mean amplitude of glycemic excursions was significantly reduced with degludec (p = 0.028), as was area under the curve for daily blood glucose level <70 mg/dL (p = 0.046). The required insulin dose was reduced up to 25% in the degludec group, although 24-h mean glucose concentrations were not different between groups. In conclusion, once or twice daily glargine was successfully replaced by a daily injection of degludec. When replacing glargine with degludec, a lower dose should be utilized to avoid hypoglycemia. Degludec is an effective and promising long-acting insulin that reduced hypoglycemia and daily blood glucose variability in participants with type 1 diabetes.
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar )


Feedback - Hokkaido University